Abstract：Objective To investigate the clinical effect of Nicorandil in the treatment of coronary slow flow (CSF), thus providing reference for more effective treatment in CSF patients. Methods A total of 126 patients who underwent coronary angiography (GAG) and diagnosed with CSF in Wuhan Third Hospital from December 2016 to June 2018 were selected as the research objects, and they were divided into control groups (64 cases) and combined treatment group (62 cases) according to the random number table method. Patients in the control group were given conventional treatment,while patients in the combined treatment group were given Nicorandil treatment on the basis of conventional treatment.Patients were followed up once a month for 6 months. The changes of symptoms, blood routine, inflammatory factors,homocysteine, and platelet aggregation rate of the two groups of patients before and after treatment were observed, and the incidence of adverse reactions between the two groups of patients after treatment was compared. Results After treatment, the total cholesterol, triacylglycerol, high-sensitivity C-reactive protein, interleukin-1, interleukin-6, endothelin-1, homocysteine, and platelet aggregation rate in both groups were lower than those before treatment, nitric oxide was higher than that before treatment, and the differences were statistically significant (P＜0.05). The total cholesterol, triacylglycerol, high-sensitivity C-reactive protein, interleukin-1, interleukin-6, endothelin-1, homocysteine, and platelet aggregation rate after treatment in the combined treatment group were lower than those in the control group, nitric oxide was higher than that in the control group, and the differences were statistically significant (P＜0.05). After treatment, the incidence rates of chest pain, arrhythmia and chest tightness of the two groups of patients were lower than those before treatment,and the differences were statistically significant (P＜0.05).The incidence rates of chest pain and chest tightness in the combined treatment group were lower than those in the control group,and the differences were statistically significant(P＜0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups (P＞0.05). Conclusion The combination of Nicorandil and conventional treatment can improve symptoms and inflammatory status in CSF patients more significantly.
Tambe AA，Demany MA，Zimmerman HA，et al.Angina pectoris and slow flow velocity of dye in coronary arteries-a new angiographic finding[J].Am Heart J，1972，84（1）：66-71.
Beltrame JF，Limaye SB，Wuttke RD，et al.Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon[J].Am Heart J，2003，146（1）：84-90.
[12]
Niu H，Wei Z，Zhang Y，et al.Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow[J].Exp Ther Med，2018，15（1）：904-908.
[13]
Sadamatsu K，Tashiro H，Yoshida K，et al.Acute effects of isosorbide dinitrate and nicorandil on the coronary slow flow phenomenon[J].Am J Cardiovasc Drugs，2010，10（3）：203-208.
京公网安备 11010502046607号